bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
a suspicion from retrospective data has just been confirmed by the paradigm trial at #asco22: adding panitumumab to standard chemo in left-sided ras wild-type mcrc is more effective than adding bevacizumab. 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.